Part 4 – Using AI to Get One Step Ahead of Antibiotic Resistance

Throughout history, humans have coalesced around moonshot culture to achieve audacious goals—from eradicating smallpox, to sequencing the human genome, to landing a spacecraft on Mars. These feats of human ingenuity didn’t happen in a vacuum, they were born from intentional innovation, a “coalition of the willing,” and a vision to outdo yesterday. This fireside chat with Drew Panayiotou, Former CMO of Pfizer and Devon Still, ex-NFL player and founder of Still Strong Foundation, explores innovations in cancer, their personal experiences with family members needing healthcare treatment, and what it will take to achieve Pfizer's next big moonshot to outdo cancer and achieve its vision, a world where people with cancer live better and longer lives.This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge. The Let's Outdo Cancer Campaign aims to focus on advances in fighting against cancer. To learn more, visit letsoutdocancer.com.

Podcasting has exploded in the last 5 years, with every celebrity, brand, and influencer investing in audio. It’s estimated that 144MM people in the U.S. listen to a podcast monthly. With scale and an ability to build audience connections, podcasts have become effective at communicating complex information in a digestible way–making them perfect for sharing science-based stories. Many have heard the term "gene therapy," but how many know what it means? How do you explain the science behind artificial intelligence or designing the Mars Rover? Audio allows us to do this, while enhancing the impact of science communications. Join the Pfizer Podcast team, NASA, UT Austin, and Wonder Media Network as they share their audio expertise and accessible approach to scientific storytelling.Featured experts:Shira Atkins, CRO & Co-Founder, Wonder Media NetworkEllen Gerstein, Head Of Digital Communications, Pfizer Inc.Katie Konans, Audio Storytelling Lead, NASAKristen Wynn, Program Manager, The University of Texas at Austin, Dell Medical School, Livestrong Cancer InstitutesThis episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge. 

In a live taping of the Science Will Win podcast, Host and Artificial Intelligence Expert Jeremiah Owyang speaks to cutting-edge healthcare leaders about the impact that AI is having on the future of cancer. Thirty years ago, the thought of a world without cancer was nothing more than a dream. Similarly, AI was considered a technology that had yet to become reality. Today, we are reimagining a future where the AI revolution will help change the trajectory of cancer as we know it.Featured experts:Edward Cox, Head & General Manager Of Digital Health & Medicines, PfizerJulie Gerberding, CEO and President, Foundation for the National Institutes of HealthMaimah Karmo, Founder & CEO, Tigerlily FoundationThis episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge. 

Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare.Featured Guests:Dame Sally Davies, UK Special Envoy for Antimicrobial ResistanceDaniel Gallego, President of the European Kidney Patient FederationRanjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, PfizerSubha Madhavan, Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data ManagementJay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development.Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichLei Zhang, Executive Director of Medicinal Chemistry, Pfizer Medicine DesignMarinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance. Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichRanjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, PfizerMarinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence.Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichJay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal ProgramsMary Lynne Van Poelgeest-Pomfret, President, World Federation of Incontinence and Pelvic Problems Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?Featured Guests:Laurie, Breast Cancer Clinical Trial ParticipantDr. Edith Mitchell, Medical Oncologist, Thomas Jefferson UniversityJulia Perkins Smith, Global Clinical Lead, PfizerJamil Rivers, CEO, Chrysalis InitiativeAdditional Resources:pfizerclinicaltrials.com/oncologypfizerclinicaltrials.compfizerestudiosclinicos.com

Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.Featured Guests:Martha Carlson, Breast Cancer Advocate & WriterDr. Edith Mitchell, Medical Oncologist, Thomas Jefferson UniversityJeff Settleman, Chief Scientific Officer, Pfizer Oncology